Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.52 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.48 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30670765 | 0.98 | CYP1A2 (0.56) | POLBCYP1A2GAACYP2D6CYP2C19 | |
| Carbamic Acid SCHEMBL28488101 | 0.89 | POLB (0.59) | POLBCYP1A2GAACYP2D6CYP2C19 | |
| SCHEMBL30523687 | 0.86 | POLB (0.47) | POLBCYP1A2GAACYP2D6CYP2C19 | |
| SCHEMBL9809283 | 0.83 | MAOB (0.47) | CSNK2A1ST14KEAP1NFE2L2MAOB | |
| SCHEMBL12313578 | 0.83 | SLC6A4 (0.68) | SLC6A4 | |
| SCHEMBL7521694 | 0.83 | TAAR1 (0.61) | POLBCYP1A2GAACYP2D6CYP2C19 | |
| SCHEMBL14449300 | 0.81 | POLB (0.59) | POLBCYP1A2GAACYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL14157113 | 0.81 | TAAR1 (0.59) | POLBCYP1A2GAACYP2D6CYP2C19 | |
| SCHEMBL22563306 | 0.81 | ST14 (0.45) | CSNK2A1ST14KEAP1NFE2L2MAOB | |
| Hydrochloric Acid SCHEMBL6574419 | 0.81 | MAOB (0.46) | POLBCYP1A2GAACYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1121372-B1 | ADENINE DERIVATIVES | PFIZER LTD (GB) | 2006-06-28 | — | — | EP | claimed |
| US-6326359-B1 | PURINE DERIVATIVES | PFIZER INC | 2001-12-04 | — | — | US | claimed |
| EP-1121372-A1 | ADENINE DERIVATIVES | Pfizer Limited (GB) | 2001-08-08 | — | — | EP | claimed |
| WO-2000023457-A1 | ADENINE DERIVATIVES | PFIZER LIMITED (GB) | 2000-04-27 | — | — | WO | claimed |
| EP-4635568-A2 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA Pharmaceuticals Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-3672954-B1 | COMPOUNDS, SALTS THEREOF AND THEIR USE FOR THE TREATMENT OF DISEASES | ACADIA PHARM INC (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250197385-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARM INC (US) | 2025-06-19 | — | — | US | disclosed |
| US-12139477-B2 | Compounds, salts thereof and methods for treatment of diseases | ACADIA PHARMACEUTICALS INC. (US) | 2024-11-12 | — | — | US | disclosed |
| CN-115667236-B | 1, 5-Dihydro-2, 4-benzodiazepine-3-one derivative and application thereof | 江苏恩华药业股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117466803-A | Compounds, salts thereof and methods for treating diseases | 阿卡蒂亚药品公司 | 2024-01-30 | — | — | CN | disclosed |
| WO-2023205415-A1 | TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF | MITOBRIDGE INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| EP-4265599-A1 | PYRIMIDINE CARBOXAMIDE COMPOUND AND USE THEREOF | Shanghai Meiyue Biotech Development Co., Ltd. (CN) | 2023-10-25 | — | — | EP | disclosed |
| US-6326359-B1 | PURINE DERIVATIVES | PFIZER INC | 2001-12-04 | — | — | US | disclosed |
| WO-2001070677-A1 | SULPHONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 2001-09-27 | — | — | WO | disclosed |
| EP-1121372-A1 | ADENINE DERIVATIVES | Pfizer Limited (GB) | 2001-08-08 | — | — | EP | disclosed |
| WO-2000023457-A1 | ADENINE DERIVATIVES | PFIZER LIMITED (GB) | 2000-04-27 | — | — | WO | disclosed |
| CN-1184423-A | Nodulisporic acid derivatives | MERCK & CO INC (US) | 1998-06-10 | — | — | CN | disclosed |
| US-4987132-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-01-22 | — | — | US | disclosed |
| EP-0279681-A2 | Saturated heterocyclic carboxamide derivatives | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1988-08-24 | — | — | EP | disclosed |
| US-4203898-A | ANTICARCINOGENIC | ELI LILLY AND COMPANY (US) | 1980-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12139477-B2 | Compounds, salts thereof and methods for treatment of diseases | SLC10A1, CYP27A1, CYP11B2 | POLB 1347/4885CYP1A2 385/4885GAA 21/4885 |
| US-20250197385-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | SLC10A1, CYP27A1, CYP11B2 | POLB 1347/4885CYP1A2 385/4885GAA 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.